$MRNA
애널리스트 3명 · 활성 토론 0건

Moderna, Inc. MRNA

현재 강세 2, 약세 1 — 양극화되고 있.

애널리스트는 강세 2 대 약세 1로 안정적입니다.

3명의 YouTube 애널리스트가 Moderna, Inc.(MRNA)를 다룹니다.

지금까지 3명의 애널리스트가 MRNA를 다루었습니다…

애널리스트 의견

애널리스트 의견

STStockCharts TV — YouTube finance analystStockCharts TV7d ago
BULL$MRNA단기기술적

$58 저항 돌파, $62 신호 반전.

MRNA는 이전 저항선인 $58을 돌파하여 $62에 근접하게 마감했으며, 이중 바닥 패턴과 강한 거래량이 추세 전환 가능성을 시사합니다.

이중 바닥 패턴 형성 후 MRNA가 지지선을 유지하며 오늘 $58 부근의 이전 고점을 돌파하고 $62 근방에서 마감했습니다. 특히 자금이 방어적 섹터로 유입된다면 이 기술적 움직임은 강세 전망을 뒷받침합니다.

"This Market Rally Faces A Big Test"
JCJack Corsellis — YouTube finance analystJack Corsellis43d ago
BULL$MRNA단기기술적

Bullish on $MRNA: ORB works in flush/EMA contexts — avoided when the setup is near “extended/no-no” index conditions.

MRNA can fit the ORB framework when the indexes are flushing and the stock is near key daily moving averages, because the “no-no” zones are described as occurring when the index is extended the other way.

MRNA is framed as a tradable ORB candidate specifically when the index action lines up with mean-reversion and snapback behavior around daily moving averages. The risk note is contextual: the approach warns against taking the same type of setups when the index tape is in the unfavorable “no-no” state.

"The Trading Session That Nearly Ruined My Month (+17% Recovery)"

next-gen shot framed as ongoing pathogen risk signal

MRNA appears to be preparing next-generation mRNA shots related to this “antivirus” threat (citing work from 2024 with Korea University), which he frames as evidence the vaccine program is implicitly tied to ongoing pathogen risk.

Next-generation mRNA vaccine development tied to 2024 research with Korea University is framed as implicit evidence that the vaccine program is linked to continuing pathogen risk rather than a standalone commercial opportunity.

""Mass Negligent Homicide" - Hantavirus Outbreak Surges As Fauci Deadline Nears"

MRNA에 대한 공식 공시는 아직 확인되지 않았습니다.